Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, will host its Q2 2025 earnings call on August 6, 2025 at 4:30 p.m. ET. The company, which maintains a pipeline of seven brain disease programs including three in clinical stages, will present financial results and provide a business update.
The event will be accessible via webcast through the company's website at www.neumoratx.com, with a replay available for 30 days post-event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.
Neumora Therapeutics (Nasdaq: NMRA), un'azienda biofarmaceutica in fase clinica focalizzata sui trattamenti per le malattie cerebrali, terrà la sua conferenza sui risultati del secondo trimestre 2025 il 6 agosto 2025 alle 16:30 ET. La società, che dispone di un portafoglio di sette programmi per malattie cerebrali, di cui tre in fase clinica, presenterà i risultati finanziari e fornirà un aggiornamento sul business.
L'evento sarà accessibile via webcast tramite il sito web dell'azienda all'indirizzo www.neumoratx.com, con una replica disponibile per 30 giorni dopo l'evento. Si consiglia ai partecipanti di registrarsi alla conferenza telefonica almeno 10 minuti prima dell'inizio.
Neumora Therapeutics (Nasdaq: NMRA), una empresa biofarmacéutica en etapa clínica enfocada en tratamientos para enfermedades cerebrales, llevará a cabo su llamada de resultados del segundo trimestre de 2025 el 6 de agosto de 2025 a las 4:30 p.m. ET. La compañía, que mantiene una cartera de siete programas para enfermedades cerebrales, incluyendo tres en etapas clínicas, presentará resultados financieros y ofrecerá una actualización del negocio.
El evento será accesible vía webcast a través del sitio web de la empresa en www.neumoratx.com, con una repetición disponible durante 30 días después del evento. Se recomienda a los participantes registrarse para la llamada de conferencia al menos 10 minutos antes del inicio.
Neumora Therapeutics (나스닥: NMRA)는 뇌 질환 치료에 중점을 둔 임상 단계의 생명공학 제약 회사로, 2025년 8월 6일 오후 4시 30분(동부시간)에 2025년 2분기 실적 발표 전화를 개최합니다. 임상 단계에 있는 3개를 포함해 7개의 뇌 질환 프로그램을 보유한 이 회사는 재무 결과를 발표하고 사업 업데이트를 제공할 예정입니다.
이 행사는 회사 웹사이트 www.neumoratx.com을 통해 웹캐스트로 시청할 수 있으며, 행사 종료 후 30일간 다시보기 서비스가 제공됩니다. 참가자는 시작 10분 전까지 컨퍼런스 콜에 등록할 것을 권장합니다.
Neumora Therapeutics (Nasdaq : NMRA), une société biopharmaceutique en phase clinique spécialisée dans les traitements des maladies cérébrales, tiendra sa conférence téléphonique sur les résultats du deuxième trimestre 2025 le 6 août 2025 à 16h30 ET. L'entreprise, qui dispose d'un portefeuille de sept programmes pour les maladies cérébrales, dont trois en phase clinique, présentera les résultats financiers et fournira une mise à jour commerciale.
L'événement sera accessible via un webcast sur le site Web de la société à l'adresse www.neumoratx.com, avec une rediffusion disponible pendant 30 jours après l'événement. Il est recommandé aux participants de s'inscrire à la conférence téléphonique au moins 10 minutes avant le début.
Neumora Therapeutics (Nasdaq: NMRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von Hirnerkrankungen spezialisiert hat, wird seine Ergebnispräsentation für das zweite Quartal 2025 am 6. August 2025 um 16:30 Uhr ET abhalten. Das Unternehmen, das über eine Pipeline von sieben Programmen für Hirnerkrankungen verfügt, darunter drei in klinischer Phase, wird finanzielle Ergebnisse vorstellen und ein Geschäftsupdate geben.
Die Veranstaltung ist über einen Webcast auf der Unternehmenswebsite www.neumoratx.com zugänglich, mit einer Wiedergabe, die 30 Tage nach der Veranstaltung verfügbar ist. Teilnehmer werden gebeten, sich mindestens 10 Minuten vor Beginn der Telefonkonferenz anzumelden.
- None.
- None.
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update.
A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
FAQ
When will Neumora Therapeutics (NMRA) report Q2 2025 earnings?
How can investors access Neumora Therapeutics' Q2 2025 earnings call?
How many drug development programs does Neumora Therapeutics have?
What time should participants register for Neumora's Q2 2025 earnings call?
